Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
NGNE
#2511
Neurogene, Inc. Common Stock
23.490
0
+21.87%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+21.87%
Monthly Change
+18.04%
6 month change
-20.16%
Year Change
-20.16%
Previous Close
19.275
0
Open
23.490
0
Bid
Ask
Low
23.490
0
High
23.490
0
Volume
39
Markets
US Stock Market
Healthcare
NGNE
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
News
Netflix, Dell among market cap stock movers on Friday
Why Is Neurogene Stock Skyrocketing Friday? - Neurogene (NASDAQ:NGNE)
Neurogene stock surges 30% on FDA breakthrough therapy status
FDA grants breakthrough therapy status to Neurogene’s Rett drug
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin
Neurogene doses multiple patients in Rett syndrome gene therapy trial
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Neurogene: From Speculation To Execution With NGN-401 (NASDAQ:NGNE)
Cantor Fitzgerald maintains Overweight rating on Taysha Gene Therapies stock
Stifel reiterates Buy rating on Neurogene stock after positive Rett data
Neurogene stock price target raised to $70 from $65 at H.C. Wainwright